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Protein stabilityThymosin β4 has multi-functional roles in cell physiology, but little is known about its mechanism(s) of
action. We previously reported that thymosin β4 stimulated angiogenesis through the induction of vascular
endothelial growth factor (VEGF). To identify the mechanism of VEGF induction by thymosin β4, we have
used a luciferase assay system with VEGF in the 5' promoter region. We also analyzed the effect of thymosin
β4 on VEGF mRNA stability and on the expression and stability of hypoxia-inducible factor (HIF)-1α. We
found that thymosin β4 induces VEGF expression by an increase in the stability of HIF-1α protein. Analysis of
the expression patterns of thymosin β4 and HIF-1α in colon cancer tissue microarray showed that thymosin
β4 and HIF-1α co-localized in these biopsies. These data show that thymosin β4 induces the expression of
VEGF indirectly by increasing the protein stability of HIF-1α.and Genetics, Kosin University
-dong, Seo-gu, Busan, 602-703,
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Thymosin β4 is the most abundant member of the β-thymosins, a
family of highly conserved 4.5-kDa proteins. Thymosin β4 is a multi-
functional protein with various biologic roles reported, such as
promoting angiogenesis [1,2], tumor metastasis [3–8], wound healing
[9,10], hair growth [11,12], anti-apoptosis [13,14], and anti-inﬂamma-
tory responses [15,16]. In addition, thymosin β4 plays key roles in
developmental processes. Thymosin β4 has been studied in chick
embryogenesis, including the development of the nervous system,
cardiovascular system, and feather buds [17]. It has been detected in the
nervous systemof the developing rat brain, and duringdifferentiation of
embryonic cells into cardiac cells, thus, suggesting that the expressionof
thymosinβ4maybe involved in the developmentof thenervous system
and the heart [18–20]. Thymosin β4 is also expressed early in the
developing tooth and may be important in dentinogenesis [21].
We previously described the up-regulation of VEGF following the
over-expression of thymosin β4 in B16-F10 mouse melanoma cells [3].
Conversely, a down-regulation of VEGF in situwas observed in thymosin
β4 knockdown hearts suggesting that appropriate VEGF expression may
require thymosin β4 [22]. Furthermore, in a study investigating thecardio-protective effects of Akt-over expressing bone marrow stem cells
(BMSCs), both thymosin β4 and VEGF were signiﬁcantly up-regulated in
the BMSCs during hypoxia, and were suggested as potential mediators of
myocardial protection [23].However, it has yet tobedetermined,whether
there is a direct interaction between thymosin β4 and VEGF, or whether
thymosin β4 mediates an effect on VEGF expression via intermediaries,
such as hypoxia-inducible factor a (HIF)-1α which is known to induce
VEGF expression [26]. A recent study showed that thymosin β4
up-regulated the HIF-1α at the protein level and induced luciferase
activity of the HRE reporter plasmid containing ﬁve HIF-1α responsive
elements (HRE) [24]. These studies suggest thatHIF-1αmaybepart of the
mechanism involved in thymosin β4-induced VEGF expression.
Here, we investigated the mechanism of induction of VEGF
expression by thymosin β4 with a luciferase assay system containing
the 5' promoter region of mouse VEGF. We also analyzed the effect of
thymosin β4 on VEGF mRNA stability using actinomycin D treatment
and real time PCR analysis. The effect of thymosin β4 on the expression
and stability of HIF-1α was also studied using real time PCR,
cyclohexamide treatment, and Western blot analysis.
2. Materials and methods
2.1. Cell culture and treatment with thymosin β4 peptide
Mouse melanoma B16-F10 cells were obtained from American
Type Culture Collection (ATCC; Manassas, VA). Cells were grown in
1245J.-O. Jo et al. / Biochimica et Biophysica Acta 1803 (2010) 1244–1251Dulbecco's modiﬁed Eagle's medium (DMEM) containing 10% fetal
bovine serum (FBS) (Invitrogen, Carlsbad, CA). For some experiments,
B16-F10 cells were cultured for 18 h in serum-free DMEM containing
a synthetic thymosin β4 peptide (1 ng to 1 μg; RegeneRx Biopharma-
ceuticals Inc, Rockville, MD). Actinomycin D (2 μg/ml) and cyclohex-
amide (100 μM) was used in the presence or absence of thymosin β4.
2.2. Luciferase reporter constructs and luciferase assay
We used a high-ﬁdelity polymerase chain reaction (PCR) system
(Roche, Indianapolis, IN) to amplify a 0.8-kb VEGF promoter region from5’ upstream region of VEGF
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Fig. 1. Transcriptional activity of the VEGF gene promoter by thymosin β4 in a HIF-1-dependen
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**pb0.001.C57/BL6mouse tail DNA. Ampliﬁcation conditions for the VEGF promoter
were 0.5 min at 95 °C, 0.5 min at 60 °C, and 0.5 min at 72 °C for 30 cycles.
These cycles were followed by a 10-min elongation step at 72 °C. The
forward and reverse primers were designed according to Shima et al.
[25] and for this ampliﬁcation contained XhoI and BglII restriction sites
(underlined), respectively (forward primer, 5-GCTAGTCTCGAGTGTTTA-
GAAGATGAACCGTA; reverse primer, 5-GCTAGT AGATCTCAAATCCCA-
GAGCACAGACT-3). The ampliﬁed product (1.2 kb) was digested with
XhoI and BglII and cloned into the XhoI and BglII sites of the pGL3-Basic
luciferase reporter vector (Promega, Madison, Wisconsin). The sequence
of the cloned mouse VEGF promoter (p-772-luc) was conﬁrmed by DNAC
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Fig. 2. Effect of thymosin β4 on mRNA and protein levels of VEGF and HIF-1α. (A) Analysis of VEGF and HIF-1α mRNA levels after treatment with various amount of thymosin β4
peptide (0.01–100 ng). Real time PCR was performed in more than three independent experiments and presented relative to the control. (B) Analysis of protein levels of VEGF and
HIF-1α after treatment with various amount of thymosin β4 (0.1–100 ng). Western blot was performed in more than three independent experiments and the band densities are
quantitated by image analysis software (Image J, NIH, Bethesda, MD). Bands densities of Western blot products are normalized to β-actin and presented relative to the control.
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[NIDCR] Core Sequence Facility, Bethesda, MD). Deletion mutants of the
VEGF promoter, including p-449-luc and p+126-luc, were generated by
restriction enzyme digestion and self-cloning luciferase vectors according
to Shima et al. [25].
Thymosin β4 cDNA was ampliﬁed from total mouse embryo RNA
(Stratagene, La Jolla, CA) by PCR [3] and cloned into pCDNA3.1
(Invitrogen, Carlsbad, CA) to over-express thymosin β4. The sequence
of the cloned mouse thymosin β4 cDNA was conﬁrmed by DNA
sequence analysis (National Institute of Dental and Craniofacial
Research [NIDCR] Core Sequence Facility, Bethesda, MD).
Transfection of B16-F10 cells was performed using FuGENE6 (Roche
Diagnostics GmbH., Mannheim, Germany) according to the manufac-
turer's instructions. Each transfection was performed with 0.5 μg of the
VEGF promoter construct. To normalize the transfection efﬁciency, the
cells were simultaneously transfected with 0.5 μg of pRL-TK vector,
which contains the thymidine kinase (TK) gene promoter and uses
Renilla luciferase as a reporter. Cells were incubated for two days after
transfection, lysed in a lysis buffer, and then analyzed for ﬁreﬂy and
Renilla luciferase activities using the Dual-Luciferase Reporter AssaySystem kit (Promega, Madison, Wisconsin). Other vectors, including
pBOS-hHIF-1, pBOS-hARNT, and pSV40promoter-HRE-Luc vectors,
were kindly provided byDr. Fujii-Kuriyama (TohokuUniversity, Sendai,
Japan) [26].
2.3. Real time PCR analysis
We used an RNA mini-prep kit (Stratagene, La Jolla, CA) to purify
total RNA from B16-F10 cells. Five micrograms of total RNA were
subjected to RT using the AfﬁnityScript™Multiple Temperature cDNA
synthesis kit (Stratagene, La Jolla, CA). Relative quantitative Real-Time
PCR was performed in a Applied Biosystems 7500 Fast Real-Time PCR
System (Applied Biosystems, Carlsbad, CA) using the SYBR® Green
PCR Master Mix (Applied Biosystems, Carlsbad, CA) according to
manufacturer's instructions with the following primer sets: for mouse
VEGF, forward: 5-GCACATAGAGAGAATGAGCTTCC-3 and reverse: 5-
CTCCGCTCTGAACAAGGCT-3; for mouse HIF-1α, forward: 5-ACCT
TCATCGGAAACTCCAAAG -3 and reverse 5-ACTGTTAGGCTCAGGT-
GAACT-3; for glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
forward: 5-AGGTCGGTGTGAACGGATTTG-3 and reverse: 5-TGTA
1247J.-O. Jo et al. / Biochimica et Biophysica Acta 1803 (2010) 1244–1251GACCATGTAGTTGAGGTCA-3. All PCR reactions were coupled to
melting-curve analysis to conﬁrm the ampliﬁcation speciﬁcity. Non-
template controls were included for each primer pair to check for any
signiﬁcant levels of contaminants. Real time PCR was performed in
more than three independent experiments and is presented relative
to the control.
2.4. Western blot analysis
Western blot analysis was conducted as described [3]. Brieﬂy,
100 μg of either cell lysate or conditioned media were separated by
electrophoresis on a Novex 4-20% Tris–glycine gel (Invitrogen,
Carlsbad, CA). Conditioned media were prepared from 106 cells
cultured in DMEM without FBS for 18 h and were concentrated with
the use of Microcon YM-3 ﬁlters (Millipore, Bedford, MA). The protein
concentrations of the lysates and conditionedmedia were determined
by the bicinchoninic acid protein assay system (Pierce, Rockford, IL),
and equal amounts of each sample were separated by electrophoresis
on Novex 4-20% Tris–glycine gels. Equal protein loading was
conﬁrmed by Coomassie blue staining of duplicate gels after
electrophoresis. The gels were incubated in a blotting buffer contain-- 1  2  3  4  5
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transferred to a nitrocellulose membrane (Invitrogen, Carlsbad, CA)
by electrotransfer. The membrane was pre-incubated for 2 h in Tris-
Buffered Saline (TBS) containing 5% skim milk and 0.05% Tween 20
(TBS-T). The membrane was incubated overnight at 4 °C in TBS-T plus
anti HIF-1α antibody (mouse monoclonal anti-HIF-1α, 1:1000
dilution; Novus Biologicals, Littleton, CO), anti-VEGF antibody (rabbit
polyclonal anti-VEGF antibody, 1:20,000 dilution; Abcam, Cambridge,
MA), and anti β-actin (mouse monoclonal anti-β-actin antibody,
1:1,000 dilution; Abcam, Cambridge, MA). The membranes were
washed ﬁve times with PBS-T and then incubated with a species-
appropriate horseradish peroxidase-conjugated secondary antibody
(Amersham Pharmacia Biotech, Piscataway, NJ) for 1 h at room
temperature. Themembraneswerewashed ﬁve timeswith TBS-T, and
bound antibody was detected with an enhanced chemiluminescence
detection kit (Amersham Pharmacia Biotech, Piscataway, NJ). West-
ern blot was performed in more than three independent experiments
and the band densities were quantitated by image analysis software
(Image J, NIH, Bethesda, MD). Band densities of Western blot products
are normalized to β-actin and presented relative to the control.- 1  2  3  4  5
Act D (2μg/ml)
- 0.1 1 10 100 Thyβ4 (ng)
-
-
+ + + + + ActD
Time (h)
HIF-1α
HIF-1α
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0
0.2
0.4
0.6
0.8
1
1.2
1.4
) Analysis of mRNA stability of VEGF and HIF-1α after treatment with actinomycin D
ent but HIF-1αmRNA levels were unchanged. (B) Analysis of the effects of thymosin β4
A stability. Real time PCR was performed in more than three independent experiments
protein stability. HIF-1α and VEGF protein stability in the presence of thymosin β4 was
ide for 2, 4, and 6 h and analyzed for the levels of HIF-1α and VEGF protein by Western
0 ng) and 100 μMof cyclohexamide for 6 h and analyzed for the levels of HIF-1α protein
ents and the band densities are quantitated by image analysis software (Image J, NIH,
ented relative to the control.
CHX                  - + + + + +
Thyβ4 (ng) - - 0.1 1 10 100
CHX                  - + + + + +
Thyβ4
(ng)
- - 0.1 1 10 100
CHX                     - 2 4 6 2 4 6
Thyβ4  (100ng) - - - - 2 4  6
Time of treatment (h)
VEGF
C
D
HIF-1α
β-actin
HIF-1α
β-actin
HIF-1α
CHX - 2 4 6 2 4 6
Thyβ4   - - - - 2 4 6
(100ng) Time of treatment (h)
CHX - 2 4 6 2 4 6
Thyβ4   - - - - 2 4 6
(100ng) Time of treatment (h)
0
1
2
3 *
0
1
2
3 **
VEGF
0
0.5
1
1.5
R
at
io
 c
on
tro
l
R
at
io
 c
on
tro
l
Fig. 3 (continued).
1248 J.-O. Jo et al. / Biochimica et Biophysica Acta 1803 (2010) 1244–12512.5. Tissue microarray
Tissue microarray slides for colon cancers were purchased from
Super Bio Chip (SuperBioChips Laboratories, Seoul, KOREA). The tumor
tissues were obtained from surgical specimens of patients. No clinical
information except the age and gender of each patient was available for
the tissue on these arrays.
2.6. Immunohistochemistry
For immunohistochemistry, tissue microarray slides were deparafﬁ-
nized and hydrated. For antigen retrieval, slides were immersed in citrate
buffer (0.01M, pH 6.0) and heated twice in amicrowave (700Wor high)
for 5 min. Slideswere permeabilized by incubation in PBS containing 0.1%
Triton X-100 for 5 min and incubated with10% normal serum in PBS for
1 h to block nonspeciﬁc antibody. Then slides were incubated with a
mixture of rabbit polyclonal antibody to thymosin β4 (1: 500 dilution;
ALPCODiagnostics,Windham,NH,USA), andmousemonoclonal antibody
to HIF-1α (1:100 dilution; Novus Biologicals, Littleton, CO) at 4 °C
overnight. After primary antibody incubation, slides were washed three
times in PBS for 5 min and incubated with secondary antibodies (AlexaFluor 546anti-mouse antibodyandAlexa Fluor 488 anti-rabbit antibodies,
Invitrogen, Carlsbad, CA) for 1 h. The slides were observed for
epiﬂuorescence with the use of a confocal laser-scanning microscope.
2.7. Statistical analysis
The proteins expression levels and number of blood vessels per area
were measured for calculation of mean values and 95% conﬁdence
intervals. Statistical signiﬁcance of differences among the groups was
determined using a two-tailed Student's T-test. P values less than .05
were considered statistically signiﬁcant.
3. Results
We previously reported that thymosin β4 induced VEGF at the
protein level in B16-F10 cells [3]. In order to elucidate themechanismof
VEGF induction by thymosin β4, we constructed a luciferase reporter
system containing the 5’ ﬂanking region ofmouse VEGF and its deletion
mutants (Fig. 1A). However, luciferase activity was not changed in all
the deletion mutants when treated with various amounts of thymosin
β4 peptides (Fig. 1B). To explain this unexpected ﬁnding, we made the
Fig. 4. Expression pattern of the thymosin β4, and HIF-1α in colon cancer. Tissue microarray slides were immunostained with rabbit polyclonal antibody to thymosin β4 (1: 500),
and with mouse monoclonal antibody to HIF-1α (1:500 dilution). Slides treated with anti-thymosin β4 and HIF-1α were then incubated with ﬂuorescence labeled secondary
antibodies (Alexa Fluor 546 anti-mouse antibody and Alexa Fluor 488 anti-rabbit antibodies through the confocal laser-scanning microscope.
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factor(s) may be involved in this process. A recent report showed that
thymosin β4 induced the expression of HIF-1α at the protein level and
activated the HRE-containing promoter [24]. We hypothesized that it is
possible that HIF-1 may be the factor mediating thymosin β4-induced
VEGF expression. Alternatively, it is possible that thymosin β4 may
promote VEGF mRNA stability instead of transcriptional activation. In
order to investigate these hypotheses, we transfected an HRE- contain-
ing luciferase vector (pSV40promoter-HRE-Luc), an HIF-1α expression
vector (pBOS-HIF1α), an HIF-1β expression vector (pBOS-Arnt), and a
thymosin β4 expression vector (pCDNA-thymosin β4) into melanoma
cells. As shown in Fig. 1C, thymosin β4 has no effect on the HRE
promoter but when treated with HIF-1 over-expression vectors, it
increased the HRE promoter activity much more than that observed
with HIF-1 alone. To determine the effect of thymosin β4 on the VEGF
promoter with HIF-1 expression vectors, we transfected the cells with
VEGF promoters containing luciferase vectors (p-772-luc, p-449-luc,
and p+126-luc), an HIF-1α expression vector (pBOS-HIF1α), and
HIF-1β expression vector (pBOS-Arnt), and a thymosin β4 expression
vector (pCDNA-thymosin β4). As shown in Fig. 1D, thymosin β4
signiﬁcantly increased the VEGF promoter activity of -772-luc contain-
ing twoHRE elementswhen treatedwithHIF-1 over-expression vectors
when compared with HIF-1 expression vectors alone, but had no effect
on the VEGF promoter activity of -449-luc containing no positive side
HRE elements. The effect of thymosin β4 peptide was also tested with
VEGF promoter luciferase vectors, HIF-1α, and HIF-1β expression
vectors (Fig. 1E). Thymosin β4 peptide showed the same pattern of
VEGF promoter inductionwith theHIF-1 over-expression vectors. A low
amount of thymosin β4 (10 ng) wasmore effective than a high amount
(100 ng). Thesedata showthat thymosinβ4 inducedVEGF transcription
in an indirect manner and that HIF-1 is involved in the process of VEGF
induction by thymosin β4.Weanalyzed theeffectof thymosinβ4on theexpressionofVEGF and
HIF-1α at themRNAandprotein level by real timePCR andWestern blot
analysis, respectively. Thymosin β4 increased the expression of VEGF at
bothmRNAand protein levels but increased theHIF-1α expression only
at theprotein level (Fig. 2A andB). TheexpressionofVEGF andHIF-1α at
the protein level was decreased at a high dose of thymosin β4 (100 ng)
suggesting that the high dose of thymosin β4 triggered feedback
inhibition.
The effect of thymosin β4 on VEGF and HIF-1αmRNA stability was
analyzed by real time PCR analysis after treatment with the transcrip-
tion inhibitor actinomycin D. After treatment with actinomycin D
(2 μg/ml), the level of VEGF mRNA was dramatically decreased but the
level of HIF-1α mRNA was not changed signiﬁcantly (Fig. 3A).
Treatment of thymosin β4 with actinomycin D had no effect on VEGF
orHIF-1αmRNAlevels (Fig. 3B). Thesedata showthat thymosinβ4does
not affect VEGF and HIF-1αmRNA stability.
Thymosin β4 increased the expression of VEGF at the mRNA level
and protein levels but had no effect on mRNA stability. It also induced
HIF-1α expression at the protein level but had no effect on HIF-1α
mRNA expression. These data suggest thymosin β4 increased HIF-1α
protein stability. To conﬁrm the effect of thymosinβ4 onHIF-1α protein
stability,we conductedWesternblot analysis after treatmentof the cells
with cyclohexamide (CHX), an inhibitor of protein synthesis. As shown
in Fig. 3C, the expression of HIF-1αwas decreased after treatment with
CHX for 6 h.When treatedwith thymosinβ4 after treatment of CHX, the
level of HIF-1α was not decreased but increased. The protein level of
VEGFwas decreased by treatment of CHX but thymosin β4 has no effect
on protein stability of VEGF (Fig. 3C). Treatment with various amounts
of thymosin β4 showed that 10 ng effectively blocked HIF-1α
degradation and furthermore 100 ng of thymosin β4 increased the
HIF-1α protein level (Fig. 3D). These data show that thymosin β4
increased HIF-1α stability and induced VEGF expression through
1250 J.-O. Jo et al. / Biochimica et Biophysica Acta 1803 (2010) 1244–1251regulation of HIF-1α protein stability. The protein level of HIF-1α
peaked in the treatment with 100 ng of thymosin β4 when co-treated
with CHX suggesting that CHX treatment block the feedback inhibition
against thymosin β4.
We analyzed the expression pattern of thymosin β4 and HIF-1α in
colon cancers which has been reported to express thymosin β4 [5,7] by
using tissue array. The expression patterns of thymosin β4, and HIF-1α
showed co-localization in more than 70% of the cancer specimens
(Fig. 4). These data show that thymosin β4, and HIF-1α are co-localized
and support our conclusion that thymosin β4 involved HIF-1α protein
stability to induce the expression of VEGF.
4. Discussion
Angiogenesis is one of the most important activities of thymosin β4
in tissue development and in malignancy. The ﬁrst identiﬁcation of a
role for thymosin β4 in angiogenesis came from its identiﬁcation in a
screen for rapidly induced (b4 h) genes following culture of human
umbilical vein endothelial cells (HUVECs) on Matrigel (basement
membrane matrix) [27]. Further, insight into the inﬂuence of thymosin
β4 on endothelial cell migration came from migration assays demon-
strating that thymosinβ4acts as a chemoattractant for endothelial cells,
stimulating directional migration (as opposed to random motility or
chemokinesis) in Boyden chamber assays [2]. Additionally, thymosinβ4
signiﬁcantly accelerated the rate of endothelial cellmigration in vivo in a
subcutaneous Matrigel plug assay [2]. Subsequently, thymosin β4 was
found to stimulate endothelial cell attachment and promote tubule
formation on Matrigel, vascular sprouting of coronary artery rings, and
angiogenesis in vivo. Nowmany reports show that thymosin β4 induces
angiogenesis by promoting migration of endothelial and other
vasculogenic cells [3,9,28] yet the precise mechanism by which
thymosin β4 directs angiogenesis and cell migration is not well deﬁned
and the role of actin binding versus other receptor-mediated events is
still a matter of debate.
We ﬁrst introduced a mechanism of how thymosin β4 induces
angiogenesis [3].We showed thatwhen thymosinβ4 is over-expressed in
B16-F10 cells, there is an increase in the number of blood vessels in solid
tumors by up-regulation of VEGF expression at the protein level. To
conﬁrm the transcriptional activation of VEGF by thymosin β4, we
analyzed here VEGF promoter activity in the presence of thymosin β4.
However, we did not ﬁnd any effect of thymosin β4 on the promoter
activity of VEGF. To explain this unexpected ﬁnding, we analyzed the
possibility that thymosin β4 either induces VEGF indirectly. Furthermore,
a recent study showed the possibility of the relationship between
thymosin β4 and HIF-1α by analyzing the effect of thymosin β4 on the
HRE reporter system [24]. These studies suggest that HIF-1αmay be part
of themechanism involved in thymosin β4-induced VEGF expression but
did not demonstrate that thymosin β4 induced the expression of HIF-1
alphaor increased the stability ofHIF-1 alpha.Here,weanalyzed theeffect
of thymosin β4 on the mouse VEGF promoter when treated with HIF-1
alpha expression vector. We also investigated expression patterns and
stabilities of VEGF and HIF-1 alpha at the RNA and protein levels by
treatmentwith thymosinβ4 to identify the role of thymosinβ4 in the up-
regulation of VEGF. We found that thymosin β4 induces the transcrip-
tional expression of VEGF by increasing HIF-1α protein stability.
In a recent study on the cardio-protective effects of Akt-over
expressing bone marrow stem cells (BMSCs), both thymosin β4 and
VEGF were signiﬁcantly induced in the BMSCs during hypoxia [23]. We
also analyzed the thymosin β4 and VEGF expressions in B16-F10 cells at
RNA and protein levels during hypoxia. The expression of VEGF was
increased at the RNA and protein levels but thymosin β4 was not
induced by hypoxia in B16-F10 cells (data not shown). These results
suggest that up-regulation of VEGF by hypoxia in B16-F10 cells is not
mediated by thymosin β4 but thymosin β4 modulates the hypoxia-
independent angiogenesis by up-regulating VEGF expression through
increasing the stability of existing HIF-1α protein.Both HIF-1α and HIF-1β mRNAs and proteins are constitutively
expressed. Only HIF-1α responds to changes in oxygen tension,
although HIF-1β, despite its apparent insensitivity to hypoxia, is
required for HIF-1 activity [29]. The process of HIF-1α activation,
including enhanced protein stability and transcriptional activity, has
been studied extensively in the past few years. The half-life of HIF-1α is
b5 min under normoxia [30,31], yet its hypoxic induction is instanta-
neous [32]. Although the term “hypoxia-inducible factor” implies
increased production at low oxygen tension, hypoxia, in fact, slows
destruction of HIF-1α. Under normoxia, HIF-1α undergoes continuous
proteolysis through the ubiquitin-proteasome pathway [33,34]. Here,
we report that thymosin β4 increases protein stability even in the
normoxic condition and that stable HIF-1α protein increases the
transcription of VEGF. These results show a new mechanism of HIF-1α
protein regulation and VEGF induction in the normoxic condition.Acknowledgments
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